Company Cash and Short-term Investments Total $253 Million
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 17 2026
0mins
Should l Buy XFOR?
Cash, cash equivalents and short-term investments totaled $253.0 million as of December 31, 2025, which management believes will enable the Company to fund its operations through 2028.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy XFOR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on XFOR
Wall Street analysts forecast XFOR stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 4.350
Low
7.00
Averages
57.75
High
120.00
Current: 4.350
Low
7.00
Averages
57.75
High
120.00
About XFOR
X4 Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on discovering and developing novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. Its lead clinical candidate is mavorixafor, a small-molecule selective antagonist of chemokine receptor CXCR4. It has developed a small-molecule, oral antagonists of the chemokine receptor C-X-C receptor type 4 (CXCR4). It has two pre-clinical candidates: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling opportunities in CXCR4-dependent disorders and primary immunodeficiencies, and X4P-002, a CXCR4 antagonist with a distribution profile and a demonstrated ability to cross the blood-brain barrier.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
X4 Pharmaceuticals Grants Inducement Awards to New Employees
- Equity Incentive Plan: On March 31, 2026, X4 Pharmaceuticals granted 32,000 stock options to new employees under the 2019 Inducement Equity Incentive Plan, aimed at attracting and retaining talent while enhancing the company's competitive edge in rare hematology diseases.
- Option Details: The options have an exercise price of $4.13 per share, equal to the closing price on the grant date, with a ten-year term and a four-year vesting schedule, reflecting the company's commitment to long-term employee contributions.
- Clinical Trial Progress: X4 is conducting a pivotal global Phase 3 trial evaluating its CXCR4 antagonist mavorixafor for chronic neutropenic disorders, with the FDA granting Fast Track designation, indicating strong market anticipation for the drug.
- Company Vision: Focused on developing innovative therapies to improve the lives of patients with rare hematology diseases, X4 leverages expertise in immune system disorders and CXCR4 biology to address significant unmet medical needs and drive long-term growth.
See More
X4 Pharmaceuticals Q4 Earnings Beat Expectations
- Earnings Highlights: X4 Pharmaceuticals reported a Q4 GAAP EPS of -$0.22, beating expectations by $0.13, indicating a positive trend in improving profitability despite still being in the red.
- Revenue Surge: The company achieved Q4 revenue of $2.57 million, a 79.7% year-over-year increase, surpassing market expectations by $0.84 million, suggesting strong product demand and enhanced market acceptance, potentially laying the groundwork for future growth.
- Stock Price Reaction: Following the earnings release, X4 Pharmaceuticals' shares rose by 4% in after-hours trading, reflecting a positive investor response to the company's performance, which may bolster market confidence and attract more investor interest.
- Industry Outlook: X4 Pharmaceuticals presented its future outlook at the Guggenheim Securities Biotech Summit, emphasizing its funded path to FDA approval, indicating the company's strategic positioning and potential growth opportunities in the biotech sector.
See More
X4 Pharmaceuticals Receives Positive EMA Opinion for Mavorixafor
- Regulatory Progress: X4 Pharmaceuticals announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for mavorixafor to treat WHIM syndrome, with a decision from the European Commission expected in Q2 2026, potentially opening significant market opportunities for the company.
- Clinical Trial Results: This positive opinion is supported by favorable outcomes from a pivotal Phase 3 trial assessing the efficacy and safety of XOLREMDI in patients aged 12 and older with WHIM syndrome, demonstrating strong clinical effectiveness and enhancing the drug's market outlook.
- Commercial Partnership Agreement: In January 2025, X4 entered into a licensing and supply agreement with Norgine, which will commercialize mavorixafor in Europe, Australia, and New Zealand following regulatory approvals, potentially generating up to $226 million in regulatory and commercial milestone payments for X4.
- Future Revenue Potential: X4 is also eligible for escalating double-digit royalties of up to the mid-twenties percentage on future net sales, providing a stable revenue stream and enhancing its competitive position in the global market.
See More
X4 Pharmaceuticals Receives Positive Opinion for WHIM Syndrome Therapy in EU
- Regulatory Milestone: X4 Pharmaceuticals' mavorixafor has received a positive opinion from the EMA's CHMP, potentially becoming the first and only therapy for WHIM syndrome in the EU, addressing a significant unmet medical need for patients with this ultra-rare disease.
- Clinical Trial Success: The 4WHIM trial demonstrated that mavorixafor significantly increased absolute neutrophil counts (ANC) and absolute lymphocyte counts (ALC), with threshold time improvements compared to placebo and a 60% reduction in infection rates, showcasing its remarkable efficacy.
- Commercial Partnership Agreement: X4 entered into a licensing and supply agreement with Norgine, which will commercialize mavorixafor in Europe, Australia, and New Zealand, allowing X4 to receive up to €226 million in milestone payments and double-digit royalties on future sales, enhancing the company's revenue potential.
- Market Access Strategy: X4 plans to collaborate with Norgine to ensure timely patient access to this critical treatment following final approval, further solidifying its market position in the rare disease sector.
See More
Sanofi Acquires Dynavax for $15.50 per Share, Totaling $2.2 Billion
- Acquisition Deal: Sanofi's agreement to acquire Dynavax for $15.50 per share, totaling approximately $2.2 billion, is expected to enhance its market presence in adult immunization, potentially driving future revenue growth.
- Stock Price Reaction: Following the acquisition announcement, Dynavax shares surged 38.6% to $15.44, indicating a positive market response that may attract further investor interest in the company.
- FDA Approval Impact: Omeros Corp's stock jumped 66.8% to $14.60 after the FDA approved YARTEMLEA for treating related conditions, reflecting strong market demand and optimistic expectations for potential revenues from new drugs.
- Market Dynamics: Companies like Edgewise Therapeutics and Agios Pharmaceuticals also saw significant stock price increases due to positive clinical trial results and FDA approvals, indicating a resurgence of activity and investor confidence in the biotech sector.
See More
Examining X4 Pharmaceuticals' Story Following Leadership Transitions and Recent Funding
Analyst Price Target Adjustments: X4 Pharmaceuticals' consensus analyst price target has decreased from $8.70 to $7.38 due to updated financing scenarios and changes in leadership, reflecting a more cautious outlook on expected returns.
Bullish and Bearish Perspectives: While Stifel maintains a Buy rating despite lowering its price target, indicating confidence in the company's long-term prospects, there are concerns about valuation and the impact of recent recapitalizations on shareholders.
Capital Raise and Strategic Restructuring: The company raised $135 million through a follow-on equity offering and announced a workforce reduction of about 50% to focus on key development initiatives, aiming for significant cost savings.
Financial Metrics Overview: Key financial metrics have been adjusted, with revenue growth expectations lowered and net profit margins increased, suggesting improved profitability despite slower sales expansion.
See More
X4 Pharmaceuticals Grants Inducement Awards to New Employees
- Equity Incentive Plan: On March 31, 2026, X4 Pharmaceuticals granted 32,000 stock options to new employees under the 2019 Inducement Equity Incentive Plan, aimed at attracting and retaining talent while enhancing the company's competitive edge in rare hematology diseases.
- Option Details: The options have an exercise price of $4.13 per share, equal to the closing price on the grant date, with a ten-year term and a four-year vesting schedule, reflecting the company's commitment to long-term employee contributions.
- Clinical Trial Progress: X4 is conducting a pivotal global Phase 3 trial evaluating its CXCR4 antagonist mavorixafor for chronic neutropenic disorders, with the FDA granting Fast Track designation, indicating strong market anticipation for the drug.
- Company Vision: Focused on developing innovative therapies to improve the lives of patients with rare hematology diseases, X4 leverages expertise in immune system disorders and CXCR4 biology to address significant unmet medical needs and drive long-term growth.
See More
X4 Pharmaceuticals Q4 Earnings Beat Expectations
- Earnings Highlights: X4 Pharmaceuticals reported a Q4 GAAP EPS of -$0.22, beating expectations by $0.13, indicating a positive trend in improving profitability despite still being in the red.
- Revenue Surge: The company achieved Q4 revenue of $2.57 million, a 79.7% year-over-year increase, surpassing market expectations by $0.84 million, suggesting strong product demand and enhanced market acceptance, potentially laying the groundwork for future growth.
- Stock Price Reaction: Following the earnings release, X4 Pharmaceuticals' shares rose by 4% in after-hours trading, reflecting a positive investor response to the company's performance, which may bolster market confidence and attract more investor interest.
- Industry Outlook: X4 Pharmaceuticals presented its future outlook at the Guggenheim Securities Biotech Summit, emphasizing its funded path to FDA approval, indicating the company's strategic positioning and potential growth opportunities in the biotech sector.
See More
X4 Pharmaceuticals Receives Positive EMA Opinion for Mavorixafor
- Regulatory Progress: X4 Pharmaceuticals announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for mavorixafor to treat WHIM syndrome, with a decision from the European Commission expected in Q2 2026, potentially opening significant market opportunities for the company.
- Clinical Trial Results: This positive opinion is supported by favorable outcomes from a pivotal Phase 3 trial assessing the efficacy and safety of XOLREMDI in patients aged 12 and older with WHIM syndrome, demonstrating strong clinical effectiveness and enhancing the drug's market outlook.
- Commercial Partnership Agreement: In January 2025, X4 entered into a licensing and supply agreement with Norgine, which will commercialize mavorixafor in Europe, Australia, and New Zealand following regulatory approvals, potentially generating up to $226 million in regulatory and commercial milestone payments for X4.
- Future Revenue Potential: X4 is also eligible for escalating double-digit royalties of up to the mid-twenties percentage on future net sales, providing a stable revenue stream and enhancing its competitive position in the global market.
See More
X4 Pharmaceuticals Receives Positive Opinion for WHIM Syndrome Therapy in EU
- Regulatory Milestone: X4 Pharmaceuticals' mavorixafor has received a positive opinion from the EMA's CHMP, potentially becoming the first and only therapy for WHIM syndrome in the EU, addressing a significant unmet medical need for patients with this ultra-rare disease.
- Clinical Trial Success: The 4WHIM trial demonstrated that mavorixafor significantly increased absolute neutrophil counts (ANC) and absolute lymphocyte counts (ALC), with threshold time improvements compared to placebo and a 60% reduction in infection rates, showcasing its remarkable efficacy.
- Commercial Partnership Agreement: X4 entered into a licensing and supply agreement with Norgine, which will commercialize mavorixafor in Europe, Australia, and New Zealand, allowing X4 to receive up to €226 million in milestone payments and double-digit royalties on future sales, enhancing the company's revenue potential.
- Market Access Strategy: X4 plans to collaborate with Norgine to ensure timely patient access to this critical treatment following final approval, further solidifying its market position in the rare disease sector.
See More
Sanofi Acquires Dynavax for $15.50 per Share, Totaling $2.2 Billion
- Acquisition Deal: Sanofi's agreement to acquire Dynavax for $15.50 per share, totaling approximately $2.2 billion, is expected to enhance its market presence in adult immunization, potentially driving future revenue growth.
- Stock Price Reaction: Following the acquisition announcement, Dynavax shares surged 38.6% to $15.44, indicating a positive market response that may attract further investor interest in the company.
- FDA Approval Impact: Omeros Corp's stock jumped 66.8% to $14.60 after the FDA approved YARTEMLEA for treating related conditions, reflecting strong market demand and optimistic expectations for potential revenues from new drugs.
- Market Dynamics: Companies like Edgewise Therapeutics and Agios Pharmaceuticals also saw significant stock price increases due to positive clinical trial results and FDA approvals, indicating a resurgence of activity and investor confidence in the biotech sector.
See More
Examining X4 Pharmaceuticals' Story Following Leadership Transitions and Recent Funding
Analyst Price Target Adjustments: X4 Pharmaceuticals' consensus analyst price target has decreased from $8.70 to $7.38 due to updated financing scenarios and changes in leadership, reflecting a more cautious outlook on expected returns.
Bullish and Bearish Perspectives: While Stifel maintains a Buy rating despite lowering its price target, indicating confidence in the company's long-term prospects, there are concerns about valuation and the impact of recent recapitalizations on shareholders.
Capital Raise and Strategic Restructuring: The company raised $135 million through a follow-on equity offering and announced a workforce reduction of about 50% to focus on key development initiatives, aiming for significant cost savings.
Financial Metrics Overview: Key financial metrics have been adjusted, with revenue growth expectations lowered and net profit margins increased, suggesting improved profitability despite slower sales expansion.
See More
